Detalles de la búsqueda
1.
Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
Cancer Sci
; 115(5): 1656-1664, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38450844
2.
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Oncologist
; 29(5): e681-e689, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38241181
3.
Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
Eur J Clin Pharmacol
; 79(4): 503-511, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36773042
4.
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
Invest New Drugs
; 40(3): 634-642, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35024985
5.
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
Invest New Drugs
; 39(1): 232-236, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32556898
6.
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Invest New Drugs
; 38(1): 211-218, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31784866
7.
Improvement strategies for successful next-generation sequencing analysis of lung cancer.
Future Oncol
; 16(22): 1597-1606, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32490705
8.
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.
Invest New Drugs
; 37(6): 1257-1265, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30937690
9.
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
Mol Cancer Ther
; 23(2): 212-222, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37802502
10.
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Target Oncol
; 19(3): 411-421, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467958
11.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Front Immunol
; 15: 1348034, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38464519
12.
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Cancer Lett
; 587: 216692, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38342232
13.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Front Oncol
; 14: 1303543, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38344209
14.
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Ther Adv Med Oncol
; 15: 17588359231177022, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37333903
15.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
JAMA Netw Open
; 6(7): e2322915, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432682
16.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
NPJ Precis Oncol
; 7(1): 12, 2023 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702855
17.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Target Oncol
; 18(6): 915-925, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902896
18.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Cancers (Basel)
; 15(20)2023 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894357
19.
Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study.
J Geriatr Oncol
; 13(2): 207-213, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602370
20.
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.
JTO Clin Res Rep
; 3(7): 100355, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35769388